<DOC>
	<DOCNO>NCT00285896</DOCNO>
	<brief_summary>GLP-1 incretin hormone simulate insulin secretion inhibits glucagon secretion glucose dependent way . Below normal plasma glucose level effect GLP-1 stop risk hypoglycemia small . However result exit effect pharmacologically relevant dos GLP-1 long-time fasting . There seem risk hypoglycemia healthy people fast period glucose load administer . The risk hypoglycemia GLP-1 administer evaluate two condition .</brief_summary>
	<brief_title>GLP-1 Infusion Long-Time Fasting</brief_title>
	<detailed_description>GLP-1 incretin hormone simulate insulin secretion inhibits glucagon secretion dependent normal plasma glucose.It also inhibit gastric empty trophic effect pancreatic beta-cells . Below normal plasma glucose level effect GLP-1 stop risk hypoglycemia small.The counter regulatory response hypoglycemia show preserve GLP-1 infusion . However result exit effect pharmacologically relevant dos GLP-1 long-time fasting . There seem risk hypoglycemia healthy people fast period glucose load administer . The risk hypoglycemia GLP-1 administer evaluate two ( 48 hour fast follow glucose-load ) condition healthy men . Also effect 24 hour blood pressure evaluate .</detailed_description>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>healthy male , age 2050 year , BMI 2030 kg/m2 , Blood pressure &lt; 140/90 mmHg , caucasian . Diabetes relative , anaemia , significant disease , smoking .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>GLP-1</keyword>
	<keyword>fast</keyword>
	<keyword>hypoglycaemia</keyword>
</DOC>